-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascelia Pharma to meet FDA on Orviglance NDA after complete response letter

PUBT·08/17/2026 09:55:55
Listen to the news
Ascelia Pharma to meet FDA on Orviglance NDA after complete response letter
  • Ascelia Pharma scheduled a Type A FDA meeting for Sept. 9, 2026 on the Orviglance New Drug Application.
  • Session will address the FDA’s Complete Response Letter issued July 2, 2026, covering clinical, quality, and regulatory topics.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascelia Pharma AB published the original content used to generate this news brief on August 17, 2026, and is solely responsible for the information contained therein.